Autolus Therapeutics plc Quarterly Operating Income (Loss) in USD from Q4 2018 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Autolus Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from Q4 2018 to Q2 2025.
  • Autolus Therapeutics plc Operating Income (Loss) for the quarter ending June 30, 2025 was -$61.2M, a 3.88% decline year-over-year.
  • Autolus Therapeutics plc Operating Income (Loss) for the twelve months ending June 30, 2025 was -$270M, a 39.4% decline year-over-year.
  • Autolus Therapeutics plc annual Operating Income (Loss) for 2024 was -$241M, a 34.3% decline from 2023.
  • Autolus Therapeutics plc annual Operating Income (Loss) for 2023 was -$180M, a 25.3% decline from 2022.
  • Autolus Therapeutics plc annual Operating Income (Loss) for 2022 was -$143M, a 1.67% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 -$270M -$61.2M -$2.29M -3.88% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$268M -$65.2M -$26.5M -68.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 -$241M -$75.9M -$22.6M -42.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 -$219M -$67.9M -$25M -58.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$194M -$58.9M -$14.6M -32.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$179M -$38.8M +$391K +1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 -$180M -$53.3M -$22.5M -72.9% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 -$157M -$42.9M -$5.56M -14.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$152M -$44.4M -$5.31M -13.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$146M -$39.1M -$2.96M -8.19% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q4 2022 -$143M -$30.8M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$37.3M Jul 1, 2022 Sep 30, 2022 10-K 2024-03-21
Q2 2022 -$39.1M Apr 1, 2022 Jun 30, 2022 10-K 2024-03-21
Q1 2022 -$36.2M +$3.69M +9.25% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-21
Q1 2021 -$169M -$39.9M -$1.31M -3.39% Jan 1, 2021 Mar 31, 2021 6-K 2021-05-06
Q4 2020 -$168M -$47.3M -$4.25M -9.86% Oct 1, 2020 Dec 31, 2020 20-F 2023-03-07
Q3 2020 -$164M -$42.7M -$7.09M -19.9% Jul 1, 2020 Sep 30, 2020 6-K 2020-11-05
Q2 2020 -$157M -$39.5M -$2.34M -6.29% Apr 1, 2020 Jun 30, 2020 6-K 2020-08-06
Q1 2020 -$154M -$38.6M -$8.41M -27.9% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-06
Q4 2019 -$146M -$43.1M -$18.1M -72.3% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-10
Q3 2019 -$128M -$35.6M Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 -$37.2M Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 -$30.2M Jan 1, 2019 Mar 31, 2019 6-K 2020-05-07
Q4 2018 -$25M Oct 1, 2018 Dec 31, 2018 20-F 2021-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.